About me
I hold a Bachelor's degree in Chemistry (Ramon Llull University, 1994) and a Bachelor's degree in Chemical Engineering (IQS, 1995). After obtaining a PhD in Organic Chemistry (University of Barcelona, 1999), I joined Lewis Kay's group in Toronto for a postdoctoral fellowship (University of Toronto, 2000-2004). I was then awarded a Ramón y Cajal research grant at the Barcelona Science Park (2004-2006) and am currently the group leader of the Precision Medicine and Metabolism laboratory at CIC bioGUNE. My research focuses on the use of nuclear magnetic resonance (NMR) to study biologically relevant proteins and enzymes, paying particular attention to the delicate balance between protein stability and dynamics. This knowledge is applied to the development of new compounds with therapeutic activity in the field of rare diseases, and has led to the creation of a spin-off company, ATLAS Molecular Pharma. I have discovered a novel pharmacological chaperone for the treatment of congenital erythropoietic porphyria, which is a repurposed drug and has been granted Orphan Drug Designation. Furthermore, I am also interested in NMR-based biofluidic metabolomics for the diagnosis of rare and prevalent diseases. I have been awarded the prize of the Royal Spanish Society of Chemistry (2004), the prize of the Spanish NMR Group (2020), the Elhuyar-Goldschmidt Prize of the German Chemical Society (2022), and was nominated for membership in the Academy of Medical Sciences of the Basque Country (2016). I am currently the president of the Spanish Chemical Biology Group.
